Case Reports of Pembrolizumab-induced Acute Inflammatory Demyelinating Polyneuropathy

Pembrolizumab is a humanized monoclonal antibody that blocks the programmed cell death 1 (PD-1) pathway, thereby enhancing antitumor immunity. As the use of immune checkpoint inhibitors becomes more prevalent, so do immune-related adverse events associated with their use. The immune-related adverse...

Full description

Saved in:
Bibliographic Details
Published in:Curēus (Palo Alto, CA) CA), 2018-09, Vol.10 (9), p.e3371
Main Authors: Manam, Rupesh, Martin, Jasmine L, Gross, Joshua A, Chaudhary, Dhishna, Chowdhary, Sajeel, Espinosa, Patricio S, Santos, Edgardo S
Format: Article
Language:English
Subjects:
Antigens
Brain research
Cancer therapies
Case reports
Cell death
Drug dosages
Electromyography
Guillain-Barre syndrome
Hospitalization
Immunoglobulins
Immunotherapy
Internal Medicine
Ligands
Medical imaging
Melanoma
Metastasis
Monoclonal antibodies
Neurology
Neurosciences
NMR
Nuclear magnetic resonance
Oncology
Patients
Targeted cancer therapy
Tumors
Ventilators
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Pembrolizumab is a humanized monoclonal antibody that blocks the programmed cell death 1 (PD-1) pathway, thereby enhancing antitumor immunity. As the use of immune checkpoint inhibitors becomes more prevalent, so do immune-related adverse events associated with their use. The immune-related adverse events linked with this class of drugs are commonly seen and most of the time are classified as mild adverse events. These are easily treated with steroids if recognition of symptomatology and treatment are promptly established. However, neurologic immune-related adverse events are less understood and have been infrequently cited in the medical literature, thus representing a challenge for clinicians.
ISSN:2168-8184
2168-8184
DOI:10.7759/cureus.3371